Theorem Clinical Research

Drug Sponsors

CFFT grants Savara Pharmaceuticals $1.7 million award

Friday, October 18, 2013 01:56 PM

Savara Pharmaceuticals has received a $1.7 million research award from Cystic Fibrosis Foundation Therapeutics(CFFT), the nonprofit drug discovery and development affiliate of the CF Foundation. The award will advance the development of AeroVanc, the first inhaled antibiotic being developed to treat the increasing number of people with cystic fibrosis (CF) who have persistent methicillin-resistant Staphylococcus aureus (MRSA) lung infection.

More... »

Moderna Therapeutics expands headquarters, laboratories

Friday, October 18, 2013 11:11 AM

Moderna Therapeutics, a developer messenger RNA therapeutics, a new treatment modality to enable the in vivo production of therapeutic proteins, has expanded their headquarters to Technology Square in Cambridge, Mass. Moderna will have up to 100 full-time employees at two locations by the end of 2013.

More... »

Clinical Site Services changes name to CSSi

Wednesday, October 16, 2013 10:48 AM

Clinical Site Services (CSS), a provider of clinical trial patient enrollment solutions, has changed its name to CSSi. The name change reflects the evolution of the company from its origins in site performance management to its position as a provider of global patient recruitment, with a focus on delivering on-time enrollment of patients in clinical studies for sponsors and CROs.

More... »

Roche to invest $880 million in global biologic medicine manufacturing network

Monday, October 14, 2013 02:16 PM

Roche plans to invest $880 million within its global manufacturing network to increase production capabilities for its biologic medicines over the next five years. The investment will be spread across sites in Penzberg, Germany; Basel, Switzerland; and Vacaville and Oceanside, Calif., U.S. Approximately 500 new jobs will be created in conjunction with the facility expansions.

More... »

Sorrento acquires Sherrington Pharmaceuticals

Friday, October 11, 2013 01:01 PM

Sorrento Therapeutics, a publicly-traded, development-stage biopharmaceutical company, has acquired Sherrington Pharmaceuticals, a privately-held company focused on the development of a chronic pain treatment for end-stage cancer patients and other severe pain indications.

More... »

Teva accelerates cost reduction program, to cut 5,000 jobs

Friday, October 11, 2013 01:00 PM

Global pharmaceutical company Teva Pharmaceutical Industries has accelerated its worldwide restructuring program, introduced in December 2012, which includes actions to divest non-core assets, increase organization effectiveness, improve manufacturing efficiency and reduce excess capacity.

More... »

Merck Serono opens global headquarters in Germany

Friday, October 11, 2013 12:58 PM

Merck Serono has opened new global headquarters in Darmstadt, Germany. The redesigned buildings feature an open office concept intended to encourage project work and collaboration. Of the 1,700 Merck Serono employees in Darmstadt, 800 work in two office buildings southeast of Merck's main campus.

More... »

PhRMA to open Middle East and Africa regional office at DuBiotech, UAE

Wednesday, October 9, 2013 02:09 PM

Pharmaceutical Research and Manufacturers of America (PhRMA) plans to establish its Middle East and Africa regional office within Dubai Biotechnology and Research Park (DuBiotech), a free zone dedicated to facilitating and fostering the growth of the life sciences industry in the UAE and a member of Tecom Investments, a developer and operator of business parks.

More... »

FDA postpones Advisory Committee meeting due to government shutdown

Wednesday, October 9, 2013 02:06 PM

ALK, a research-driven global pharmaceutical company focusing on allergy prevention, diagnosis and treatment, has announced that due to the U.S. government shutdown, the FDA has temporarily postponed the Allergenic Products Advisory Committee meeting scheduled for Nov. 6 to discuss the Biologic License Application (BLA) for the investigational grass allergy immunotherapy (AIT) tablet. The FDA has not yet confirmed a new date for the Advisory Committee meeting.

More... »

Delcath Systems announces reorganization, 33% of workforce cut

Monday, October 7, 2013 03:54 PM

Delcath Systems, a specialty pharmaceutical and medical device company focused on oncology, has completed a strategic reorganization, eliminating 21 positions, or approximately 33% of its global workforce. The company expects this reorganization, in conjunction with other cost saving measures, to significantly lower cash utilization.

More... »

Subscribe to The CenterWatch Monthly



Browse by:


October 20

Toronto Star, with FDA data, exposes weaknesses in Health Canada's clinical trial, inspection oversight

Crowdsourcing effort aims to fund updated online social media guide for sponsor interaction with patients

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly


Today's fastest, most economical sponsors
Standout sponsors reveal how they shorten regulatory, clinical cycle times

From the trenches: Sites' eye view of state of the industry
CW’s first site focus groups uncover frustration with 'progress,' but a passion for their mission

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly


Reality of costs and impact rain on Sunshine Act
Concerns mount over compliance burden on CROs, sponsors, unanticipated consequences for research

Cloud computing expanding into all areas of clinical trial conduct
Benefits outweigh the complexities, challenges of finding right vendors

Already a subscriber?
Log in to your digital subscription.

Purchase the August issue.

Subscribe to
The CenterWatch Monthly.


Featured Jobs